147 related articles for article (PubMed ID: 33819778)
1. Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.
Nielsen T; Kristensen SR; Gregersen H; Teodorescu EM; Pedersen S
Thromb Res; 2021 Jun; 202():108-118. PubMed ID: 33819778
[TBL] [Abstract][Full Text] [Related]
2. Plasma Thrombin Generation and Sensitivity to Activated Protein C Among Patients With Myeloma and Monoclonal Gammopathy of Undetermined Significance.
Crowley MP; Kevane B; O'Shea SI; Quinn S; Egan K; Gilligan OM; Ní Áinle F
Clin Appl Thromb Hemost; 2016 Sep; 22(6):554-62. PubMed ID: 26759370
[TBL] [Abstract][Full Text] [Related]
3. Patients with multiple myeloma and monoclonal gammopathy of undetermined significance have variably increased thrombin generation and different sensitivity to the anticoagulant effect of activated protein C.
Ghansah H; Debreceni IB; Váróczy L; Rejtő L; Lóczi L; Bagoly Z; Kappelmayer J
Thromb Res; 2023 Mar; 223():44-52. PubMed ID: 36708689
[TBL] [Abstract][Full Text] [Related]
4. Platelet hyperactivation in multiple myeloma is also evident in patients with premalignant monoclonal gammopathy of undetermined significance.
O'Sullivan LR; Meade-Murphy G; Gilligan OM; Mykytiv V; Young PW; Cahill MR
Br J Haematol; 2021 Jan; 192(2):322-332. PubMed ID: 32478420
[TBL] [Abstract][Full Text] [Related]
5. Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma.
Crowley MP; Quinn S; Coleman E; Eustace JA; Gilligan OM; O'Shea SI
J Thromb Thrombolysis; 2015 Feb; 39(2):245-9. PubMed ID: 25271000
[TBL] [Abstract][Full Text] [Related]
6. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.
Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Cairns DA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
Lancet Haematol; 2017 Dec; 4(12):e584-e594. PubMed ID: 29146225
[TBL] [Abstract][Full Text] [Related]
7. Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance.
Kristinsson SY; Björkholm M; Schulman S; Landgren O
Semin Hematol; 2011 Jan; 48(1):46-54. PubMed ID: 21232658
[TBL] [Abstract][Full Text] [Related]
8. Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics.
Greenberg AJ; Rajkumar SV; Vachon CM
Blood; 2012 Jun; 119(23):5359-66. PubMed ID: 22354002
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of serum levels of Dickkopf-1 (DKK-1) in monoclonal gammopathy of undetermined significance and multiple myeloma].
Ščudla V; Petrová P; Pika T; Lochman P; Minařík J; Bačovský J; Srovnalík K
Cas Lek Cesk; 2015; 154(4):181-8. PubMed ID: 26357861
[TBL] [Abstract][Full Text] [Related]
11. Extracellular vesicle-associated procoagulant phospholipid and tissue factor activity in multiple myeloma.
Nielsen T; Kristensen SR; Gregersen H; Teodorescu EM; Christiansen G; Pedersen S
PLoS One; 2019; 14(1):e0210835. PubMed ID: 30640949
[TBL] [Abstract][Full Text] [Related]
12. Baseline and treatment-related changes in thrombin generation in patients with multiple myeloma.
Tiong IS; Rodgers SE; Lee CH; McRae SJ
Leuk Lymphoma; 2017 Apr; 58(4):941-949. PubMed ID: 27931131
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
14. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
[TBL] [Abstract][Full Text] [Related]
15. Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
Chang SH; Gumbel J; Luo S; Thomas TS; Sanfilippo KM; Luo J; Colditz GA; Carson KR
Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2055-2061. PubMed ID: 31501149
[TBL] [Abstract][Full Text] [Related]
16. Multiple myeloma and its treatment contribute to increased platelet reactivity.
Mitchell JL; Khan D; Rana RH; Kriek N; Unsworth AJ; Sage T; Bye AP; Laffan M; Shapiro S; Thakurta A; Grech H; Ramasamy K; Gibbins JM
Platelets; 2023 Dec; 34(1):2264940. PubMed ID: 37822056
[TBL] [Abstract][Full Text] [Related]
17. Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma.
Greenberg AJ; Rajkumar SV; Larson DR; Dispenzieri A; Therneau TM; Colby CL; Phelps TK; Kumar SK; Katzmann JA; Kyle RA; Slager SL; Vachon CM
Br J Haematol; 2012 May; 157(4):472-5. PubMed ID: 22629552
[TBL] [Abstract][Full Text] [Related]
18. Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma.
Greenberg AJ; Cousin M; Kumar S; Ketterling RP; Knudson RA; Larson D; Colby C; Scott C; Vachon CM; Vincent Rajkumar S
Eur J Haematol; 2013 Sep; 91(3):193-195. PubMed ID: 23647020
[TBL] [Abstract][Full Text] [Related]
19. Increased activity of procoagulant factors in patients with small cell lung cancer.
Pedersen S; Kristensen AF; Falkmer U; Christiansen G; Kristensen SR
PLoS One; 2021; 16(7):e0253613. PubMed ID: 34288927
[TBL] [Abstract][Full Text] [Related]
20. The effect of corn trypsin inhibitor, anti-tissue factor pathway inhibitor antibodies and phospholipids on microvesicle-associated thrombin generation in patients with pancreatic cancer and healthy controls.
Hellum M; Franco-Lie I; Øvstebø R; Hauge T; Henriksson CE
PLoS One; 2017; 12(9):e0184579. PubMed ID: 28910348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
